Clinical Use of Cyclosporin in Rheumatoid Arthritis

Drugs

Volumn 50, Issue 1, 1995, Pages 26-36

  Richardson, Charles ^a   Emery, Paul ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AURANOFIN; CYCLOSPORIN A; GOLD DERIVATIVE; IMMUNOMODULATING AGENT; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; GINGIVA HYPERPLASIA; HEADACHE; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIPOPHILICITY; LYMPHOCYTE FUNCTION; META ANALYSIS; ORAL DRUG ADMINISTRATION; RASH; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS; T LYMPHOCYTE ACTIVATION; TREMOR;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; DRUG COSTS; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE;

EID: 0029609502     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199500501-00005     Document Type: Article

References (53)

1. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome
2. Rheumatoid arthritis: a disease of T lymphocyte/macrophage immunoregulation
3. DR 4 subtype frequencies in rheumatoid arthritis indicate that Drβl is the major susceptibility locus within the HLA class II region
4. Lymphocytapharesis — a feasible treatment for rheumatoid arthritis
5. Dissection of the mechanism of immune injury in rheumatoid arthritis using total lymphoid irradiation
6. Synovial T lymphocyte specific immune response to Chlamydia trachomatis in Reiter’s disease
7. T lymphocyte clones illuminate pathogenesis and effect therapy of experimental arthritis
8. Effects of the new anti-lymphocyte cyclosporin A in animals
9. Cyclosporin A inhibits interleukin 2 and gamma interferon synthesis by human thymocytes
10. Lymphokine and non-lymphocytic mRNA levels in stimulated TR cells: kinetics, mitogen requirements and effects of cyclosporin A
11. Anti-CD3 antibody-induced expression of both p55 and p75 chains of the high affinity interleukin 2 receptor on human T lymphocytes is inhibited by cyclosporin A
12. Coordinate expression of src family proto-oncogenes in T cell activation and its modulation by cyclosporine
13. Modes of action of FK506, cyclosporin A, and rapamycin
14. The mechanism of action of FK-506 and cyclosporine A
15. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation
16. The regulation of expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells
17. The role of CD40 in the regulation of humoral and cell-mediated immunity
18. Cyclosporin A inhibits CD40 ligand expression in T lymphocytes
19. Absorption of cyclosporine A after oral dosing
20. Cyclosporine clinical pharmacokinetics
21. Cyclosporin: a review of the pharmacokinetic properties, immunosuppressive efficacy and tolerability of a microemulsion-based formulation (Neoral®)
22. Relative bioavailability of a new oral form of cyclosporin A in patients with rheumatoid arthritis
23. Cyclosporine pharmacokinetics and variability from a microemulsion formulation — a multicentre investigation in kidney transplant patients
24. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients
25. A cost effectiveness analysis of cyclosporin in cadaveric kidney transplantation
26. Cyclosporin: a pharmacoeconomic evaluation of its use in renal transplantation
27. Use of Sandimmun Neoral in renal transplant patients. Part A
28. A double blind randomised study of Sandimmun Neoral versus Sandimmun in new renal transplant recipients: results after 12 months
29. Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: a randomised double blind study
30. Cyclosporin A in rheumatoid arthritis: a double-blind placebo-controlled study. The Norwegian Arthritis Study Group
31. Low dose cyclosporin versus placebo in patients with rheumatoid arthritis
32. Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients
33. Cyclosporin Ain rheumatoid arthritis; overview of efficacy
34. The comparative efficacy and toxicity of second line drugs in rheumatoid arthritis: results of two meta analyses
35. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicentre study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group
36. Effect of cyclosporin on serum creatinine in patients with rheumatoid arthritis
37. Conclusions of an international review. The use of cyclosporin A in rheumatoid arthritis
38. Role of endothelin in cyclosporine induced glomerular dysfunction
39. Acute cyclosporine induced vasoconstriction is mediated by endothelin I
40. Increased factor VIII as an index of vascular injury in cyclosporin nephrotoxicity
41. Concerns after cyclosporin therapy
42. Malignancies in rheumatoid arthritis patients treated with cyclosporin A
43. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressant treatment
44. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study
45. Cyclosporin nephrotoxicity
46. A randomized double blind, 24 week controlled study of low dose cyclosporine versus chloroquine for early rheumatoid arthritis
47. Methotrexate in rheumatoid arthritis
48. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis
49. Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies)